TIAA Trust National Association Has $13.08 Million Stake in Teva Pharmaceutical Industries Ltd. $TEVA

TIAA Trust National Association trimmed its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 36.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 418,972 shares of the company’s stock after selling 237,843 shares during the period. TIAA Trust National Association’s holdings in Teva Pharmaceutical Industries were worth $13,076,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 19.2% in the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock valued at $1,402,945,000 after purchasing an additional 7,255,083 shares in the last quarter. Menora Mivtachim Holdings LTD. boosted its stake in shares of Teva Pharmaceutical Industries by 1.1% in the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock valued at $786,190,000 after purchasing an additional 427,000 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 14.8% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company’s stock valued at $1,167,323,000 after purchasing an additional 4,820,000 shares in the last quarter. Norges Bank acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $1,098,060,000. Finally, Rubric Capital Management LP boosted its stake in shares of Teva Pharmaceutical Industries by 1.8% in the 2nd quarter. Rubric Capital Management LP now owns 26,000,000 shares of the company’s stock valued at $435,760,000 after purchasing an additional 450,000 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Up 3.3%

Shares of NYSE TEVA opened at $34.35 on Wednesday. The company has a 50 day simple moving average of $33.00 and a 200 day simple moving average of $31.81. The firm has a market cap of $39.50 billion, a PE ratio of 25.83, a price-to-earnings-growth ratio of 3.39 and a beta of 0.84. Teva Pharmaceutical Industries Ltd. has a 1 year low of $14.99 and a 1 year high of $37.35. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The business had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. On average, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.36 EPS for the current year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 21,258 shares of the firm’s stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $35.31, for a total transaction of $750,619.98. Following the completion of the transaction, the executive vice president owned 63,647 shares in the company, valued at approximately $2,247,375.57. This trade represents a 25.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Richard Daniell sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the transaction, the executive vice president owned 55,755 shares of the company’s stock, valued at approximately $1,973,727. The trade was a 34.98% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 421,470 shares of company stock worth $14,570,945 over the last quarter. 0.54% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

TEVA has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Saturday. UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Truist Financial raised their price target on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Finally, Barclays raised their price target on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $41.78.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.